)
MBX Biosciences (MBX) investor relations material
MBX Biosciences TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Key program updates and clinical milestones
Achieved strong phase II results in hypoparathyroidism and advanced an obesity candidate, MBX 4291, into the clinic in 2025.
Planning to initiate a global phase III study for canvorparotide in Q3 2026, with phase II one-year follow-up data expected in Q2.
Anticipating 12-week multiple ascending dose data for MBX 4291 in Q4, targeting improved tolerability and once-monthly dosing.
Expanding the obesity portfolio with new candidates targeting amylin and glucagon, with development candidates to be declared in Q2 and Q3.
Strong financial position with cash runway into 2029, supporting all planned clinical and pre-commercial activities.
Technology platform and differentiation
Precision Endocrine Peptides (PEP) platform enables slow, steady drug release for improved tolerability and less frequent dosing.
Platform incorporates programmable prodrug technology and fatty acylation to extend drug action and reduce dosing frequency.
Technology is clinically validated and designed by a leading peptide chemist, supporting best-in-class product candidates.
Differentiated PK profile aims to provide both monthly dosing and better tolerability, especially in obesity treatments.
Clinical data highlights and expectations
Canvorparotide phase II showed significant response rates in hypoparathyroidism, with 79% responder rate at six months and high patient retention.
One-year open-label extension data will include bone mineral density and safety, with expectations for maintained response rates.
Phase III study design will align with established endpoints and sample sizes from comparable trials, with a focus on convenience and efficacy.
MBX 4291 phase I/II studies in obesity will assess PK, tolerability, and weight loss, with a stepwise approach to dose selection and titration.
Next MBX Biosciences earnings date
Next MBX Biosciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage